The Swedish Cancer Society has decided on the research grants for 2024. Researchers from the Department of Oncology-Pathology at Karolinska Institutet received a total of over 70 million SEK.
Åsa Carlsson Tedgren receives a total of 3,000,000 SEK for the project "Brachytherapy dosimetry - development of methods and tools to improve treatment planning and dose verification" for the years 2025-2027.
Hanna Eriksson receives 3,000,000 SEK for the project "Strategies for improving the management and survival in cutaneous melanoma: From early detection to treatment of metastatic disease" for the years 2025-2027, as well as 9,000,000 SEK for the clinical treatment study "Augmented Melanoma responses with Amlexanox and Immune-based Therapy with checkpoint inhibitors in BRAF negative inoperable stage III or stage IV melanoma progressing on immune checkpoint inhibitors - the MelAmITh trial" for the years 2025-2029.
Marianne Farnebo receives 4,500,000 SEK for the project "Characterization of RNA-mediated DNA repair and its therapeutic potential" for the years 2025-2027.
Theodoros Foukakis receives 4,500,000 SEK for the project "Unravelling the mechanisms of resistance to antibody-drug conjugates in breast cancer" for the years 2025-2027, as well as 14,000,000 SEK for the clinical treatment study "A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE" for the years 2025-2027.
Hildur Helgadottir receives 3,000,000 SEK for the project "Translational melanoma research with focus on genetic susceptibility, diagnostics, treatment optimization and survival" for the years 2025-2027.
Thomas Helleday receives 7,500,000 SEK for the project "Targeting DNA repair in cancer treatments" for the years 2025-2027.
Rolf Lewensohn receives 5,250,000 SEK for the project "Biomarkers and advanced modelling to personalize high dose precision radiotherapy/stereotactic body radiotherapy (SBRT) alone and combined with pharmaceutical agents in non-small cell lung cancer" for the years 2025-2027.
Andreas Lundqvist receives 5,250,000 SEK for the project "The role of natural killer cells in cancer immunotherapy against solid tumors" for the years 2025-2027.
Laura Orellana receives 3,000,000 SEK for the project "First atomic-level mapping of Glioblastoma: searching for 'hidden' drivers" for the years 2025-2027.
Alexander Valdman receives 1,600,000 SEK for the project "Advanced radiation therapy in the treatment of rectal cancer" for the years 2025-2026.
Klas Wiman receives 5,250,000 SEK for the project " Targeting mutant TP53 for improved cancer therapy" for the years 2025-2027.
Anders Österborg receives 3,000,000 SEK for the project "Precision therapy of chronic lymphocytic leukemia (CLL) and lymphoma: from new targets and drug development, via clinical translational studies, to real-world analyses and academic vaccine trials" for the years 2025-2027.
Arne Östman receives 6,000,000 SEK for the project "Discovery and targeting of immune-regulatory tumor and lymph node fibroblasts" for the years 2025-2027.
